Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropinirole CR Add-on vs Levodopa Increase in Early PD
NCT00363727Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2003
- Primary completion
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ropinirole in Parkinson's disease (PD) (2 arms), sponsored by GSK. Primary endpoint: Time to onset of dyskinesia at 104 weeks. Started Dec 2003; status: completed.
02
Drugs
ropinirole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00363727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363727.